A Phase 3 interventional study of gabapentin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 22 sites in Japan. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Epilepsies, Partial by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · Viatris Inc..
Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 12th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 15 studies in Epilepsies, Partial by Viatris Inc. is open now. The open studies under Epilepsies, Partial, anywhere →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 136 across the 13 interventional studies, 678 across the 2 observational. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Epilepsies, Partial by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: gabapentin
Orally administered gabapentin
Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)
Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. Severe AEs: those which interferes significantly with participant's usual function. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.
Time frame: up to 53 weeks
Response Ratio
The Response Ratio calculated by the following equation : Response Ratio = (T minus B) divided by (T plus B), where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).
Time frame: Up to 52 weeks
Responder Rate
Responder Rate was defined as the percentage of subjects with a 50 percent or greater reduction in the seizure frequency per 28 days for the 52-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period of the previous study A9451162 (NCT00603473).
Time frame: Up to 52 weeks
Percent Change in Seizure Frequency
Percent change in seizure frequency (PCH) was calculated as follows: PCH = 100\*(T minus B) divided by B, where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).
Time frame: Up to 52 weeks
| Milestone | Gabapentin |
|---|---|
| Started | 65 |
| Completed | 44 |
| Not completed | 21 |
| Withdrew: Adverse event | 4 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Choice of other treatment | 1 |
| Withdrew: Visit failure against planned | 1 |
Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. Severe AEs: those which interferes significantly with participant's usual function. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.
| Participants | Gabapentin |
|---|---|
| All-causality adverse events (AEs) | 58 |
| Treatment-related AEs | 13 |
| All-causality serious AEs | 2 |
| Treatment-related serious AEs | 0 |
| All-causality severe AEs | 1 |
| Treatment-related severe AEs | 0 |
| Discontinuation due to all-causality AEs | 4 |
| Discontinuation due to treatment-related AEs | 2 |
| Dose reduction due to all-causality AEs | 2 |
| Dose reduction due to treatment-related AEs | 2 |
The Response Ratio calculated by the following equation : Response Ratio = (T minus B) divided by (T plus B), where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).
| Ratio | Gabapentin |
|---|---|
| Week 1 to 8 (n=65) | -0.263 ± 0.3141 |
| Week 9 to 16 (n=60) | -0.256 ± 0.3513 |
| Week 17 to 24 (n=58) | -0.300 ± 0.3671 |
| Week 25 to 36 (n=54) | -0.280 ± 0.3753 |
| Week 37 to 52 (n=47) | -0.327 ± 0.3712 |
Responder Rate was defined as the percentage of subjects with a 50 percent or greater reduction in the seizure frequency per 28 days for the 52-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period of the previous study A9451162 (NCT00603473).
| Percentage of participants | Gabapentin |
|---|---|
| Week 1 to 8 (n=65) | 35.4 (23.9 to 48.2) |
| Week 9 to 16 (n=60) | 40.0 (27.6 to 53.5) |
| Week 17 to 24 (n=58) | 39.7 (27.1 to 53.4) |
| Week 25 to 36 (n=54) | 40.7 (27.6 to 55.0) |
| Week 37 to 52 (n=47) | 46.8 (32.1 to 61.9) |
Percent change in seizure frequency (PCH) was calculated as follows: PCH = 100\*(T minus B) divided by B, where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).
| Percent change | Gabapentin |
|---|---|
| Week 1 to 8 (n=65) | -34.2 (-100.0 to 63.1) |
| Week 9 to 16 (n=60) | -33.0 (-100.0 to 99.8) |
| Week 17 to 24 (n=58) | -42.0 (-100.0 to 112.5) |
| Week 25 to 36 (n=54) | -41.6 (-100.0 to 110.7) |
| Week 37 to 52 (n=47) | -49.2 (-100.0 to 131.7) |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gabapentin | — | 2/65 (3.1%) | 48/65 (73.8%) |
| Event | Gabapentin |
|---|---|
| BRONCHOPNEUMONIARespiratory, thoracic and mediastinal disorders | 1/65 |
| ENCEPHALOPATHYNervous system disorders | 1/65 |
| Event | Gabapentin |
|---|---|
| NasopharyngitisInfections and infestations | 28/65 |
| SomnolenceNervous system disorders | 10/65 |
| InfluenzaInfections and infestations | 9/65 |
| PyrexiaGeneral disorders | 8/65 |
| DiarrhoeaGastrointestinal disorders | 7/65 |
| Dental cariesGastrointestinal disorders | 5/65 |
| VomitingGastrointestinal disorders | 4/65 |
| BronchitisInfections and infestations | 4/65 |
| PharyngitisInfections and infestations | 4/65 |
| Upper respiratory tract infectionInfections and infestations | 4/65 |
| Age, Customized(Participants) | Gabapentin |
|---|---|
| 3-4 years | 8 |
| 5-12 years | 42 |
| 13-16 years | 15 |
| Sex: Female, Male(Participants) | Gabapentin |
|---|---|
| Female | 27 |
| Male | 38 |
The record gives a start of May 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →